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Abstract
Objective: Evidence that cannabis use impairs cognitive function in 
humans has been accumulating in recent decades. The purpose of this 
overview is to update knowledge in this area with new findings from 
the most recent literature. Method: Literature searches were conducted 
using the Web of Science database up to February 2010.  The terms 
searched were: “cannabi*” or “marijuana”, and “cogniti*” or “memory” 
or “attention” or “executive function”, and human studies were reviewed 
preferentially over the animal literature. Discussion: Cannabis use 
impairs memory, attention, inhibitory control, executive functions 
and decision making, both during the period of acute intoxication and 
beyond, persisting for hours, days, weeks or more after the last use of 
cannabis. Pharmacological challenge studies in humans are elucidating 
the nature and neural substrates of cognitive changes associated with 
various cannabinoids. Long-term or heavy cannabis use appears to result 
in longer-lasting cognitive abnormalities and possibly structural brain 
alterations. Greater adverse cognitive effects are associated with cannabis 
use commencing in early adolescence. Conclusion: The endogenous 
cannabinoid system is involved in regulatory neural mechanisms that 
modulate processes underlying a range of cognitive functions that are 
impaired by cannabis. Deficits in human users most likely therefore 
reflect neuroadaptations and altered functioning of the endogenous 
cannabinoid system.  
Descriptors: Cannabis; Cannabinoids; Cognition; Physiological 
processes/drug effects; Neurobehavioral manifestations
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Resumo
Objetivo: Evidências de que o uso de cannabis prejudica funções cognitivas 
em humanos têm-se acumulado nas décadas recentes. O propósito desta revisão 
é o de atualizar o conhecimento nesta área com novos achados a partir da 
literatura mais recente. Método: As buscas na literatura foram realizadas 
utilizando-se o banco de dados Web of Science até fevereiro de 2010.  Foram 
buscados os termos “cannabi*” ou “marijuana” e “cogniti*” ou “memory” 
ou “attention” ou “executive function”, e os estudos em humanos foram 
revisados preferencialmente em relação aos estudos em animais. Discussão: 
O uso de cannabis prejudica a memória, a atenção, o controle inibitório, as 
funções executivas e a tomada de decisões, tanto durante como após o período 
de intoxicação aguda, persistindo por horas, dias, semanas ou mais após o 
último uso. Os estudos de desafio farmacológico em humanos estão elucidando 
a natureza e os substratos neurais das alterações cognitivas associadas a vários 
canabinoides. O uso pesado ou de longo prazo de cannabis parece resultar 
em anormalidades cognitivas mais duradouras e possivelmente em alterações 
cerebrais estruturais. Efeitos cognitivos adversos maiores estão associados ao 
uso de cannabis quando este começa no início da adolescência. Conclusão: 
O sistema canabinoide endógeno está envolvido nos mecanismos de regulação 
neural que modulam os processos subjacentes a uma gama de funções cognitivas 
que estão prejudicadas pela cannabis. Os déficits em usuários humanos muito 
provavelmente refletem, portanto, neuroadaptações e o funcionamento alterado 
do sistema canabinoide endógeno.
Descritores: Cannabis; Canabinoides; Cognição; Processos fisiológicos/efeitos 
de drogas; Manifestações neurocomportamentais
Introduction
Concerns regarding the adverse consequences of cannabis use 
continue to grow. This is well founded given that cannabis is the 
most widely used illicit substance in the world, with use often 
beginning in adolescence, a key period for neural and psychosocial 
development. 
While the cognitively impairing effects of cannabis during 
acute intoxication have been acknowledged for some time, an 
accumulating body of evidence indicates that long-term or heavy 
cannabis use results in definite but subtle cognitive impairments 
that persist beyond the period of acute intoxication. The extent 
to which such deficits persist in the longer-term remains a 
controversial area for debate within the field of human cannabis 
research. Some studies demonstrate cognitive dysfunction in 
cannabis users during intoxication and for several hours following 
smoking,1,2 others show impairment for a few days,3,4 and yet 
others have shown lasting impairments for more than a month 
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function, and in brief, evidence from animal studies of acute and 
chronic administration of cannabinoids. We group the studies 
reviewed according to the primary cognitive domains identified 
as being affected by cannabis: attention, inhibition, working 
memory/executive functions and verbal memory. 
Method
Literature searches were conducted using the Web of Science 
database from January 2007 through February 2010 to update 
previous reviews performed by the authors with select literature to 
incorporate in this specific overview of the area. The terms searched 
were: “cannabi*” or “marijuana” and “cogniti*” or “memory” or 
“attention” or “executive function” and human literature was 
reviewed preferentially over animal literature.
Discussion
1. Acute effects on human cognition
During the acute intoxication, cannabis induces perceptual 
distortions, and impairs memory and concentration. Recent years 
have seen a revival of interest in examining the acute effects of 
cannabinoids on cognition in humans, with greater application of 
prospective, double-blind, placebo-controlled cross-over designs, 
and with particular interest in relation to understanding the 
psychotomimetic effects of cannabis. 
A range of attentional processes are impaired by cannabis 
acutely. Impaired performance on sustained attention (eg. on 
continuous performance tasks), selective, focused and divided 
attention tasks, as well as in preattentive sensory memory have 
been demonstrated following acute doses of cannabis (THC or 
cannabis extract) to humans.16-19 Impaired performance, in terms 
of accuracy, increased error rates and slowed reaction times, has 
been shown to be dose-related in some studies.18 Tolerance may 
develop to some of the acute effects of cannabis in regular users. 
For example, Ramaekers et al. found impaired performance on 
a divided attention task following high dose 500μg/kg THC 
only in occasional but not heavy users, whereas both occasional 
and heavy users exhibited inhibitory control deficits in a Stop 
Signal task.19 Altered inhibitory processing is evident following 
acute intoxication, in particular through impulsive responding.20 
Hart et al. found evidence of a greater incidence of premature 
responding during acute intoxication in a range of tasks, discussing 
this in terms of failures of inhibitory control over inappropriate 
responses.21 Acute administration of THC increased impulsive 
responding on a Stop Signal Task, but did not affect Go/NoGo 
task performance in one study,20 although McGuire et al. showed 
in an imaging study that THC attenuated activation in the right 
inferior frontal cortex during a Go/NoGo task.22 
O’Leary et al. showed that 20mg of THC had dramatic effects 
in occasional cannabis users on regional cerebral blood flow during 
the performance of a dichotic auditory selective attention task, 
but that these changes were not task-related.17 Acute effects of 
cannabinoids on electrophysiology have been demonstrated in 
infrequent cannabis users for the mismatch negativity (MMN) 
component of the event-related potential (ERP) (MMN being 
following cessation of use.5 Understanding the persistence of 
cognitive deficits associated with cannabis use is not a simple 
matter of organising the literature by cognitive domains to 
determine which kinds of tasks may elicit shorter- or longer-
lasting effects of cannabis, because comparisons across studies are 
very much confounded by varying levels of exposure to cannabis 
(if not other substances as well). Elucidating the nature and 
extent of cognitive dysfunction resulting from cannabis use will 
require significant further research to determine the parameters 
of use that result in cognitive deficits across a range of tasks and 
cognitive domains. 
Various parameters of cannabis use and their relationship to 
cognitive impairment can be examined when looking at deficits 
that persist for a period of 24 hours or longer. Relationships 
between cognitive performance and frequency of cannabis use 
may indicate a residual effect of acute or chronic intoxication 
that would likely dissipate with the reduction or cessation of use. 
Associations with the dose of cannabis used might similarly reflect 
a residual effect, or in the case of cumulative dose of exposure, may 
indicate more enduring dose-related brain changes. Associations 
with duration of use imply a more enduring impairment, 
rather than one resulting from cannabinoid residues, and one 
which likely reflects actual alterations to brain function over 
the long term and gradual neuroadaptation. The age of onset of 
cannabis use has received much attention in recent years. This is 
in light of evidence that the age of initiation of cannabis use is 
decreasing,6-9 with concerns regarding exposure during the critical 
neurodevelopmental period of early adolescence and a recognition 
that the adolescent brain is more susceptible to drug insult.10  
The extent to which cognitive deficits resulting from cannabis 
may be reversible upon cessation of use is inconclusive. One study 
suggests function is recovered within one month of abstinence,3 
another study indicates that recovery does not occur after 28 days 
of monitored abstinence,5 and others suggest that partial recovery 
may occur.11,12 With the recent reporting of regional structural 
brain changes in long-term heavy cannabis users (reduction 
in hippocampal and amygdala volumes),13 research has yet to 
examine the extent to which such alterations may be reversible 
with abstinence.  
Cognitive impairment in cannabis users is most often detected in 
memory, attention and inhibitory control and executive functions. 
There is no doubt that the endogenous cannabinoid system plays 
a critical role in these functions and that their disruption by acute 
cannabis administration is cannabinoid receptor (CB
1
) mediated. 
Novel and specific roles of different cannabinoids in cannabis plant 
matter [eg. THC versus cannabidiol (CBD)] are increasingly being 
elucidated. We have previously reviewed the literature to 2007 in 
the context of the similarity between cognitive deficits in cannabis 
users and those observed in schizophrenia14 and as specific to 
memory function.15 This paper will update our knowledge with 
evidence from the most recent studies of cognitive function in 
human users with a focus on the long-term effects of cannabis use. 
We also consider recent research elucidating the effects of acute 
cannabis administration in humans, studies of brain structure and 
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an index of preattentive sensory memory)23 and the P300 
component (an index of the allocation of attentional resources 
and updating of memory traces).24 Interestingly, Juckel et al.23 
found no effect of a relatively low dose of THC alone (10mg) on 
the mismatch negativity but an enhancement of the component 
when THC was co-administered with 5.4mg CBD, pertinent 
to the proposed antipsychotic properties of CBD. Mismatch 
negativity is diminished in people with schizophrenia.25,26 On 
the other hand, Roser et al.24 showed with the same doses that 
both THC alone and THC with CBD reduced the auditory P300 
amplitude, which is also known to be reduced in schizophrenia 
and other clinical populations.   
D’Souza et al. conducted a rigorous investigation of the effects 
of intravenous THC administered to healthy volunteers who had 
experience with cannabis use but who were not heavy users.27 
THC induced transient positive and negative schizophrenia-
like symptoms and impaired working memory, verbal memory, 
distractibility and verbal fluency. Similarly, Morrison et al. report 
induction of positive psychotic symptoms and deficits in verbal 
episodic memory and executive function following administration 
of intravenous THC.28 Short-term memory problems are among 
the most frequently self-reported consequences of cannabis use by 
individuals who use the drug and are commonly reported reasons 
for seeking to quit or reduce cannabis use. Deficits in verbal 
learning and memory are perhaps the most robust impairments 
associated with acute cannabis use2,16,27-29 and impaired immediate 
and delayed free recall of information was emphasised in one recent 
review of the acute effects of cannabis on memory function,29 while 
another described evidence for difficulties in manipulating the 
contents of working memory, failure to use semantic processing 
and organisation to optimise episodic memory encoding, and 
impaired retrieval performance.30
Ilan et al. found that acute intoxication resulted in greater 
intrusion errors during recognition memory, and those subjects who 
were most affected by cannabis showed a reduced ERP difference 
between previously studied words and new distractor words, 
suggesting a disruption of neural mechanisms underlying memory 
for recent study episodes.16 Curran et al.2 found that a high dose 
of THC (15mg) resulted in no learning occurring over a 3-trial 
selective reminding task, while Bhattacharyya and McGuire et al. 
reported a series of neuroimaging studies of the effects of orally 
administered 10mg THC or 600mg CBD on the neural bases 
of verbal learning.22,31,32 They found that the effects of cannabis 
on verbal learning were mediated through its influence on left 
temporal activity (particularly parahippocampal), with modulation 
also of medial prefrontal and anterior cingulate activity, during 
encoding or retrieval of information. These studies also elucidated 
the neural basis of the anxiogenic or anxiolytic effects of THC and 
CBD, respectively, as pertinent to understanding the propensity for 
cannabis to induce psychotic symptoms.  Other recent neuroimaging 
studies of acute administration effects of cannabioids have been 
reviewed by Martin-Santos et al.33 
Working memory is disrupted by acute cannabis use.16,27,34 
Performance, electroencephalogram (EEG), and ERP measures 
were impaired on a spatial n-back task after smoked cannabis,16 
and acute administration of THC impaired delay-dependent 
discrimination within working memory in a delayed matching 
to sample task.34 Conversely, in another study, acute THC 
administration was found to spare working memory but impair 
episodic memory in infrequent cannabis users, with no residual 
effects 24 or 48 hours later.21 Regular but infrequent cannabis 
users showed dose-dependently impaired performance (greater 
errors) on a Sternberg memory task following acute administration 
of THC17 and these have been associated with reduced frontal-
midline EEG theta power.35 
Thus, further evidence has accumulated for a disruption 
of attention, memory, and inhibitory control following acute 
administration of cannabis to humans, with some elucidation 
of the neural substrates of these effects, including evidence of 
differential effects of different cannabinoids (such as THC and 
CBD). It appears also that the response to acute cannabinoid 
administration is mediated by cannabis use history and the 
development of tolerance to the acute effects in some cognitive 
tasks, but insufficient research has determined in any systematic 
way the parameters of cannabis use that lead to the development 
of tolerance, the doses that may or may not elicit impaired 
performance in regular users, or the cognitive tasks that are 
amenable to tolerance. For example, Boucher et al. showed that 
impairments in spatial working memory in rats are resistant 
to tolerance after extended administration of THC.36 Nor has 
research determined whether or how regular users may develop 
compensatory strategies during the acute intoxication to facilitate 
performance that might otherwise be impaired. For example, in 
a risky decision-making task, Rogers et al. showed a reduction of 
risky behaviour following low dose sublingual administration of 
THC to healthy young adults (not regular cannabis users), with 
an adoption of more cautious cognitive strategies to compensate 
for the perceived disruption of effective decision making by 
cannabis.37 Regular users, due to their greater experience with 
cannabis, might be more likely to develop alternate compensatory 
strategies, but this hypothesis remains to be tested.  Another study 
of decision making as assessed by the Iowa Gambling Task found 
no disruption to risky behaviour, only a slowing of performance, 
in daily cannabis users during acute intoxication.38 
2. Long-term effects on human cognition
Studies of long-term and heavy cannabis users, tested in the 
unintoxicated state, have continued to investigate residual or 
persistent effects of cannabis on cognitive function, with gradually 
greater control over confounds, and more attention to the 
parameters of cannabis use. 
1) Attention
Sustained attention, most often measured by continuous 
performance tasks (CPTs), is inconsistently impaired. Pope et 
al. found performance on CPTs to be insensitive to chronic 
cannabis use in adults,3 but Jacobsen et al. found that adolescent 
cannabis users made significantly more errors than non-using 
controls and increased errors trended toward an association 
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with greater exposure to cannabis.39 A recent study examined 
sustained attention in 132 long-term cannabis users divided into 
an early onset group (those who had commenced cannabis use 
prior to the age of 15 years) and a late onset group (≥ 15 years).40 
Early onset users performed significantly worse on the sustained 
attention task, with no performance differences between the late 
onset group and controls. However, even in the absence of overt 
performance deficits, lower glucose metabolism in orbitofrontal, 
temporal, hippocampal and parahippocampal regions was 
observed during CPT performance in regular cannabis users.41 A 
study of preattentive pre-pulse inhibition (PPI) attributed poor 
performance by chronic cannabis users to deficits in sustained 
attention, which were also associated with greater frequency of 
cannabis use.42
Selective and divided attention deficits in chronic cannabis 
users have been shown to be related to duration, frequency, 
and age of onset of use.11,12,43-48 Long-term users have difficulty 
filtering out irrelevant information, a deficit that became more 
pronounced the longer that cannabis had been used.11,12,43,44,46 
Further, only partial recovery was evident after a mean abstinence 
period of two years and no improvement with increasing months 
of abstinence, suggesting partial recovery may occur relatively 
soon after cessation of use and enduring impairment may reflect 
longer-lasting neuroadaptations.11,12 Early onset of cannabis use 
(i.e. prior to 16 years) was a strong predictor of attentional deficits 
during adulthood,47 and even relatively light use of once a week was 
related to some attentional dysfunction in young adults.48 Heavy 
users also showed a slowing of information processing during 
selective attention, as indexed by the P300 component which 
became increasingly delayed the more frequently that cannabis 
was used.44,46 This research provided evidence of differential 
deficits associated with frequency versus duration of cannabis 
use, reflecting shorter- versus longer-lasting effects.44,46 P300 
amplitude, thought to reflect the allocation of attentional resources 
and reflect inhibitory processes, has also been found to be reduced 
in early onset users,49 as well as in adult cannabis users.43,46   
2) Inhibition
As cited above under acute effects, impaired inhibitory 
processing can be assessed through behavioural tasks such as the 
Stroop, Go/NoGo and a variety of decision-making and gambling 
tasks, and is also impaired in long-term cannabis users.4,5,50-55 
Such tasks require the selection of an appropriate response whilst 
simultaneously inhibiting the inappropriate response. It has 
been suggested that the endocannabinoid system may modulate 
dopaminergic prefrontal cortical and accumbal activity and 
contribute to inappropriate incentive salience to irrelevant stimuli, 
which may underlie attentional and inhibitory processing and 
decision-making deficits.14,56,57 Imaging studies show altered 
dorsolateral prefrontal cortical (DLPFC) and anterior cingulate 
(ACC) activation during the interference condition of the Stroop 
Task, despite reasonable task performance in cannabis users54 and 
1-month abstinent cannabis users.50 Performance on the Stroop 
task is inconsistently impaired in chronic cannabis users,3-5,40,46 but 
poorer performance has been associated with various parameters of 
use (duration, dose, early onset)4,5,40,58 that may interact with low 
IQ,5 and with altered electrophysiology.58 Similarly, in a Go/NoGo 
task, adolescent cannabis users’ task performance was adequate 
following one month abstinence, however altered activation was 
observed in frontal and parietal brain regions, with users requiring 
increased neural effort during the inhibition condition to maintain 
performance levels.59 In chronic adult users also with adequate 
inhibitory control performance, commission errors increased and a 
diminished capacity for behaviour monitoring and error-awareness 
was associated with hypoactivity in the ACC and right insula.55  
3) Working memory and other executive functions
Working memory is the temporary encoding and manipulation 
of information that is a core component of executive functions of 
cognition; the involvement of the cannabinoid system in working 
memory has been well documented.14,57 Executive function tasks 
have been found to be impaired in both acute and chronic cannabis 
use (e.g. verbal fluency, Wisconsin Card Sorting Task, Ravens 
Progressive Matrices, Tower of London),3-5,60-62 but few studies have 
addressed working memory directly in cannabis users and this is an 
area that is receiving increasing interest. Both adolescent and adult 
chronic cannabis users have shown impaired working memory 
on several measures from the Cambridge Neuropsychological 
Test Automated Battery (CANTAB) including Rapid Visual 
Information Processing, Pattern Recognition Memory, Spatial 
Recognition Memory, Spatial Span, Spatial Working Memory 
and Visuospatial Paired Associate Learning.63,64 Impairments in 
visuospatial working memory may in part be due to deficits in basic 
temporal processing of saccades during oculomotor function.65 
Performance on an n-back auditory working memory task was 
shown to be impaired as memory load increased in abstinent 
adolescent cannabis users, with some evidence of altered regional 
brain activation emerging during nicotine withdrawal.66 Other 
tasks such as the Sternberg working memory task have shown no 
performance deficits in abstinent adolescents or young adults, 
but altered regional brain activation (prefrontal and parietal) 
that was related to task novelty, as opposed to practice, was 
reflective of greater effort being required to achieve the task.67,68 
Further neuroimaging studies indicate that cannabis users recruit 
additional brain regions in a compensatory manner in order to 
achieve adequate performance on working memory tasks.33,69,70 
In a recent study of verbal fluency, a task that relies heavily on 
executive functions, McHale et al. found that young adult cannabis 
users with recent use in the past week generated fewer words than 
those abstinent for at least one week, and both generated fewer 
words than non-user controls.62 The authors suggested some 
recovery of cognitive ability with abstinence, but this may have 
been confounded by frequency of use as the abstinent group 
comprised twice/weekly users, whereas users in the recent use 
group smoked 5-6 times/week. 
4) Verbal memory and other memory processes
Verbal memory is consistently impaired in chronic cannabis 
users, with significantly impaired performance on word list 
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learning tasks (e.g. Rey Auditory Verbal Learning Task (RAVLT), 
the California Verbal Learning Task (CVLT), and Buschke’s 
Selective Reminding Task).4,5,46,60,71-73 These studies have been 
extensively reviewed elsewhere, together with some early 
neuroimaging studies of verbal memory in cannabis users.14,15,46,73,74 
Overall, the evidence suggests that long-term or heavy cannabis 
users show impaired encoding, storage, manipulation and 
retrieval mechanisms.15 Users learn fewer words across trials and 
recall fewer words particularly after interference or delay. Several 
studies have shown that these deficits are variously attributed to 
duration of cannabis use,4 frequency of use,3 or cumulative dosage 
effects.5 Some studies have shown recovery of memory function 
following a period of 28 days abstinence,3 others have shown 
that such deficits persist after this period,5 while others suggest 
at least partial recovery (Solowij, unpublished data). In the study 
that showed recovery, this was less apparent when cannabis use 
was commenced at an early age.61 Verbal memory was found 
to be impaired in adolescent cannabis users63 and minimum 23 
day-abstinent adolescents and associated with lifetime episodes of 
use.75 Prospective memory has been demonstrated to be impaired 
in adolescent76 and young adult users,62,76 particularly time-based 
prospective memory.62
Recent neuroimaging studies have sought to elucidate the acute 
effects of THC and other cannabinoids (eg. CBD) on neural 
substrates subserving verbal memory, as discussed above,32,33 or 
attempted to relate brain structural changes in cannabis users 
to verbal memory deficits. For example, Yücel et al. found 
significantly reduced hippocampal volumes in long-term heavy 
cannabis users, who were also significantly impaired on the RAVLT, 
but memory performance was unrelated to hippocampal volumes.13 
Such complex verbal learning tasks likely involve functional 
connectivity across a wide range of brain regions, and impaired 
performance is likely to be associated more with the functional 
activation of those regions, rather than their structure. A recent 
electrophysiological study in chronic users found poor word 
recall and alteration of the ERP subsequent memory effect during 
encoding, a component thought to originate in the hippocampal 
region, and this alteration was associated with a longer duration 
of cannabis use and an earlier onset of use.77  
More specific hippocampal-dependent tasks, such as pictorial 
associative memory tasks, have also been investigated in one 
week abstinent cannabis users.78,79 Task performance did not 
differ between moderately-using young adults and non-user 
controls but recall accuracy decreased as a function of exposure to 
cannabis, and decreased activation was observed in users in bilateral 
parahippocampal regions and in the right DLPFC during learning.78 
However, a study of adolescents found increased activation in the 
fusiform/parahippocampal area, inferior frontal gyrus, DLPFC, 
superior parietal cortex and the ACC,79 suggestive of increased 
neural effort. A study of hippocampal-dependent face-name learning 
in young adult frequent users found impaired learning, short- and 
long-term memory, and hypoactivation of frontal and temporal 
regions with concomitant hyperactivation of parahippocampal 
regions during learning, reflective of both functional deficits and 
compensatory processes.80 When different studies have shown 
hypoactivation or hyperactivation in the same regions during 
performance of similar tasks (eg. Stroop),50,54 this may be due to 
variable parameters of cannabis use, such as the extent of exposure 
or age of onset, but further research is required to understand when 
and under what conditions increased or decreased activation is likely 
to manifest as well as the extent to which other brain regions are 
recruited to compensate for inefficiency. 
5) Other cognitive functions
Cannabis alters the perception of time, both during the acute 
intoxication and in some studies of chronic users.4,21,46,57 Typically, 
time is underestimated – the subjective experience is of time 
passing more slowly. Time estimation involves the ability to judge 
and plan the temporal order of behavioural events in order to allow 
the successful adaptation of behaviour.57 These processes may be 
underpinned by cannabinoid modulation of cortical glutamatergic 
and striatal dopaminergic transmission, and the neural substrates 
implicated include the cerebellum, basal ganglia, prefrontal cortex, 
and parietal cortex.57 Chronic cannabis users have been shown 
to be impaired in a classical delayed eye-blink conditioning task 
that reflects cerebellar functional integrity (cerebellar-dependent 
associative learning),81 and recent data suggest cerebellar structural 
alterations in chronic cannabis users.82   
Since cannabis alters mood during the acute intoxication, 
interest has grown in examining emotion and affect processing 
in chronic cannabis users. Gruber et al. examined regional brain 
activation to masked affective stimuli in heavy cannabis users 
and found altered frontal and limbic activity, with decreased 
activation of anterior cingulate and amygdala regions compared 
to controls, and differential effects for masked happy versus angry 
faces.83 Two studies of acute cannabis administration also found 
modulation of amygdala activity during processing of fearful 
faces.84,85 We reported significantly reduced amygdala volumes in 
long-term heavy cannabis users13 but it is not yet known whether 
this is associated with emotional or affect processing deficits. 
Altered affective processing may pose difficulties for effective 
communication and decision making, particularly if cingulate 
driven inhibition of inappropriate emotional responses became 
problematic. Other recent neuroimaging research has examined 
reward processing mechanisms in chronic users, showing increased 
cerebellar and ventrostriatal activation during reward anticipation, 
of which the latter was correlated with the duration of cannabis 
use and lifetime dose of exposure.86 In a study of neural activation 
underlying motor function, chronic cannabis users showed 
diminished activity of the supplementary motor cortex and area 
BA32, persisting after 28 days of abstinence, despite adequate 
response execution,87 indicating incomplete recovery of optimal 
motor planning and execution.
3. Brain structure and function
Evidence for structural brain changes in cannabis users has 
been lacking: a number of studies have found no or few global 
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or regional changes in brain tissue volume or composition,78,88,89 
but some found grey and white matter density changes globally90 
or in parahippocampal areas.91 In a recent review92 we examined 
the evidence for structural brain alterations in cannabis users and 
found that of 13 studies, the majority using MRI, the evidence 
was inconsistent. Where differences were found between users and 
non-users, they were most apparent in association with greater 
dose of exposure to cannabis and were most often localised to the 
hippocampal region.
Using more sensitive measures and assessing cannabis users 
with far greater exposure to cannabis than previous studies, a 
recent study from our own group13 found significant reduction 
of bilateral hippocampal (12%) and amygdala (7%) volumes in 
adults with a mean 20 years of near daily use compared to age, 
gender, and IQ matched non-user controls. The reduction of left 
hippocampus was dose-related, correlating with the cumulative 
dose of exposure to cannabis over the past 10 years, suggesting a 
causal effect. These results accord with evidence of hippocampal 
toxicity from the animal literature where animals were exposed to 
similar large doses over comparable proportions of their lifespan 
and showed decreases in neuronal volume, neuronal and synaptic 
density, and dendritic length of CA3 pyramidal neurons.93-96 That 
the cannabis users of our study had used three times more cannabis 
over their lifespan than those of a study of users with a similar 
duration of use but no hippocampal alteration observed,97 suggests 
that there may a threshold of cumulative exposure beyond which 
these changes in the brain may manifest.  
Age of onset of cannabis use may also be a critical factor, with 
potentially greater deleterious effects to the brain when cannabis 
use is commenced during significant periods of neurodevelopment, 
such as adolescence. Early onset cannabis users (before age 17) 
were found to have smaller whole brain volumes, lower percent 
cortical grey matter, higher percent white matter and increased 
cerebral blood flow compared to later onset users.90 A recent study 
has reported altered cortical gyrification in the frontal lobe and 
abnormal age-related changes to gyrification and cortical thickness 
in adolescent and young adult users.98 
Several studies have now reported on diffusion tensor imaging 
(DTI) measures of white matter structural integrity in cannabis 
users. Two studies found few differences between cannabis users 
and controls,54,99 whereas increasing evidence for pathology 
has come from more recent studies of young adult100,101 and 
adolescent102,103 cannabis users, in the corpus callosum and various 
fronto-temporal, occipito-frontal and posterior connections that 
develop during adolescence. It is suggested that cannabis use, 
particularly during adolescence, may affect the trajectory of normal 
brain maturation resulting in white matter aberrations, which may 
underlie compromised cognitive processing.  We have also reported 
cerebellar white matter reduction in adult long-term heavy users.82  
Further evidence of diminished neuronal and axonal integrity 
comes from a magnetic resonance spectroscopic study showing 
dose-related changes in DLPFC, ACC and putamen/globus 
pallidum, but not hippocampus.104 Changes in regional cerebral 
blood volume during 28 days of supervised abstinence have been 
reported, with some evidence for frontal normalisation with 
continued abstinence, but persistence of alterations in temporal 
and cerebellar regions.105 Acute and chronic effects of cannabis 
have also been examined on levels of nerve growth factor and 
brain-derived neurotrophic factor (BDNF) in serum, showing 
some evidence of lowered resting levels in cannabis users,106,107 
and cannabinoid modulation of these proteins is evident from a 
growing number of preclinical studies. 
4. Animal research
A wealth of preclinical research now shows an unequivocal role 
for the endogenous cannabinoid system in attention, memory, 
executive functions, inhibitory control, and multiple other 
cognitive processes, and that these are impaired following both 
acute and chronic cannabinoid administration.14,57,108,109 Even 
a single administration of an ultra-low dose of THC (0.001-
0.002mg/kg) has been shown to result in long-term cognitive 
impairments in mice (3 weeks to 4 months post-injection).110,111 
Animal studies support the notion that the developing brain 
is more susceptible to the acute and chronic effects of exogenous 
cannabinoids, particularly the hippocampus.112-114 Evidence 
is building from studies in which animals have been exposed 
prenatally or during the pubertal/adolescent period, with greater 
immediate adverse effects on cognition and behaviour observed 
in comparison to animals exposed during adulthood, as well as 
such effects persisting into adulthood with no further cannabinoid 
exposure.10,112-117  
Cannabinoid effects are prominent in the hippocampus118,119 
and depend on interactions with GABA(A) receptors.120 Further, 
modulatory mechanisms of the endocannabinoid system on 
prefrontal cortical and striatal dopamine and glutamate transmission 
are strongly supported by preclinical evidence.57 In line with human 
studies, potentiation and antagonism of cannabinoid-induced 
spatial working memory deficits in rats have also been shown to be 
dependent on the ratio between THC and CBD.121    
Conclusion
There is good evidence now that long-term heavy cannabis 
use results in cognitive deficits that have been shown to increase 
as a function of frequency, duration, dose, and age of onset of 
cannabis use. There is growing recognition that cannabis users 
are impaired on many of the same types of cognitive tests on 
which people with schizophrenia are also impaired,14 and recent 
research has sought to elucidate the neural substrates of impaired 
cognition during acute intoxication. These research directions 
will inform the mechanisms by which cannabis may trigger 
psychotic symptoms or episodes, as the association between 
cannabis use and schizophrenia is compelling122,123 and considered 
a significant public health concern. The endogenous cannabinoid 
system is altered in schizophrenia124,125 but insufficient research 
has addressed the nature of alterations to this system following 
chronic cannabis use in otherwise healthy humans. 
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The endocannabinoid system appears to be unequivocally 
involved, either directly or indirectly (through interactions with 
other neuromodulators), in the cognitive deficits resulting from 
cannabis exposure.57,113 Its dysfunction may be inferred from 
cannabinoid challenge studies and research with chronic cannabis 
users. Future research utilising CB
1
 receptor probes and improved 
analytic techniques for assessing endocannabinoids in humans125 
should enhance our understanding of the role of this system in 
cognitive impairment. There are individual differences in response 
to cannabis in the short- and long-term, and understanding what 
constitutes a susceptibility to greater adverse effects126 must be a 
priority for further research. Genetic research will inform specific 
vulnerabilities toward the development of cognitive deficits 
following exposure to cannabis, as have been identified already in 
relation to variations in the catechol-O-methyltransferase (COMT 
Val158Met) gene, involved in regulating dopaminergic transmission 
and metabolism.127 There is some evidence for structural brain 
changes in long-term heavy cannabis users and animal research 
continues to explicate the mechanisms of action of cannabinoids 
on cognition and brain function. Together, the knowledge gleaned 
from these studies will inform not only a greater understanding of 
adverse effects of cannabinoids, but the potential for therapeutic 
applications of cannabinoids.128 A wealth of integrative data from 
multimodal neuroimaging studies of humans is expected to provide 
significant advances in this field in coming years.  
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